RPG Life Sciences Limited — Earnings Release 2025

Apr 28, 2025

==> picture [507 x 75] intentionally omitted <==

April 28, 2025

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

Symbol: RPGLIFE

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Scrip code: 532983

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2025.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited,

RAJESH Digitally signed by RAJESH RAMESH RAMESH SHIRAMBEKAR Date: 2025.04.28 SHIRAMBEKAR 22:09:20 +05'30'

Rajesh Shirambekar Head – Legal & Company Secretary

Encl.: as above

==> picture [74 x 42] intentionally omitted <==

==> picture [160 x 62] intentionally omitted <==

Q4 FY25: Revenue Up by 13% Y-o-Y and PBT before exceptional items Surges 41% Y-o-Y. FY25: Revenue Up by 12% Y-o-Y and PBT before exceptional items Surges 28% Y-o-Y with EBITDA Margin Expanding from 23.3% to 26.4% Y-o-Y.

Mumbai, 28 April, 2025 : RPG Life Sciences Limited has announced its financial results for the fourth quarter and year ended March 31, 2025.

Mumbai, 28 April, 2025: RPMarch 31, 2025.	G Life Sciences Limited has announced its financ	ial results for the fourth quarter and year ende
		Y-o-Y PBT before exceptional items
Q4 FY25 Highlights	Y-o-Y Revenue from operations
	Rs. 143.09 crores – upfrom Rs. 126.99 crores	Rs. 25.00 crores – upfrom Rs. 17.74 crores
Fullyear FY25 Highlights	Rs. 653.43 crores – upfrom Rs. 582.05 crores	Rs. 150.28 crores – upfrom Rs. 117.84 crores

RPG Life Sciences, a part of RPG Enterprises, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT before exceptional items by 41% Y-o-Y for Q4 FY25, maintaining the upward trajectory in EBITDA margins, which improved from 17.6% to 21.4% Y-o-Y. Revenue from operations registered a growth of 13% Y-o-Y for Q4 FY25. For full year FY25 too, the company posted a jump in PBT before exceptional items by 28% Y-o-Y and recorded EBITDA margin expansion from 23.3% to 26.4% Y-o-Y. Revenue from operations at Rs 653.43 crores registered a growth of 12% Y-o-Y for FY25.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q4 FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 13% and 41% respectively Y-o-Y. The full year EBITDA margin surged from 23.3% to 26.4% Y-o-Y, retaining its upward trajectory Y-o-Y for the last 6 years.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets.

We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth.

Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory.

The Company has built sizeable cash surplus of ~Rs. 168 crores from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to ~Rs. 266 crores. We are actively pursuing inorganic opportunities to accelerate business growth.

On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 250% plus a special dividend of 50% on the face value of Rs. 8 each for FY25, subject to the approval of shareholders at the ensuing Annual General Meeting, thus maintaining an upward trajectory of dividend for the last 6 years.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4.8 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovationled technology businesses.

Media Contact: Rashmi Menon – 88980 20577 | rashmi@rpg.in

==> picture [134 x 27] intentionally omitted <==